Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Target price


17.05.24 / Tradegate WKN: A12GD6 / Name: Viking / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Viking Therapeutics Inc Stock

Heavy losses for Viking Therapeutics Inc today as the stock fell by -€1.980 (-3.120%).
Currently there is a rather positive sentiment for Viking Therapeutics Inc with 5 Buy predictions and 0 Sell predictions.
As a result the target price of 100 € shows a very positive potential of 62.28% compared to the current price of 61.62 € for Viking Therapeutics Inc.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Viking Therapeutics Inc stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Viking Therapeutics Inc in the next few years

S********** s********
C******** o* t** e**********
M***** P*******
W********* I********* f** t** n*** y****
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Viking Therapeutics Inc vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Viking Therapeutics Inc -3.120% -9.886% -1.123% 173.745% 252.416% 1157.808% -
Ardelyx Inc. 0.340% -0.416% 16.992% 98.564% 24.360% 28.357% -
Evolus Inc 5.130% 4.237% 11.818% 41.379% 35.912% 70.833% -
Salarius Pharmaceuticals Inc. 7.850% -5.069% -4.630% -67.040% -25.766% -98.502% -99.992%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-05-16

Upon initial examination of Viking's financial statements, the company's financial situation seems challenging, which is a common scenario in the biotechnology and medical research industry. Companies in this field often face significant losses and capital expenditures before reaching profitability. The next step is to provide a detailed analysis of the company's financials to understand the pros and cons better.

1. Strong Cash Position: Viking's cash position has improved over the years, despite a slight decline observed in the recent quarter. At the end of 2020, the company held $29,117,000 in cash, which grew to $36,632,000 at the end of 2022. This implies that the company has enough liquidity to support its ongoing operations and invest in future opportunities.

2. Substantial Investments: Cash flow statements reveal that between 2020 and 2022, Viking consistently invested in its business, totaling over $120 million in short-term investments. These investments can create long-term value for the company and are a positive sign for its shareholders.


Is Viking Therapeutics Stock a Buy?:
Is Viking Therapeutics Stock a Buy?

Investing in clinical-stage pharmaceutical companies comes with a lot of risk, but also a lot of potential upside. When such a company delivers a successful product that passes regulatory muster --

How Viking Therapeutics Stock Could 30x:
How Viking Therapeutics Stock Could 30x

Viking Therapeutics (NASDAQ: VKTX) has been one of the few bright spots in the healthcare sector this year. The biotech's shares have stormed higher by almost 300% year to date on the back of its

Is Viking Therapeutics the Best Biotech Stock for You?:
Is Viking Therapeutics the Best Biotech Stock for You?

Viking Therapeutics (NASDAQ: VKTX) isn't a household name, but if its plans to commercialize a powerful anti-obesity medicine come to fruition, it may well become one. Though it has yet to